LifeSpot Health gives update on Cannabis agenda.


LifeSpot Health (ASX: LSH) has provided an update on their medicinal cannabis development.

LifeSpot has launched their medical cannabis vaporiser, Medihale, which is currently in trial with some medical and recreational brands in USA and Canada. They are also developing a new device features that uses finger print security to child proof the device, along with Bluetooth integration.

Due to increasing demand in USA and Canada, LifeSpot is currently hiring a Business Development lead to handle these territories.

Gregor Schommer, Managing Director Bodytel (LifeSpot’s German subsidiary) said, “Ee are very pleased with the awareness and quality relationships we have built with many of the major cannabis players in North America and Europe. We are well placed in Germany to service Europe at this current stage of growth and product development requests, however, we clearly see our first supply contracts coming from the rapidly growing North American region.

The Business Development Lead appointment is a critical next step for us. The product offering of our Bodytel software licensing, combined with Seng-Vital vaporiser hardware sales is clearly providing innovation not seen elsewhere in the rapidly growing vaporising category. LifeSpot now offers a great range of product and services our new Business Development lead can now take to the market.”

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Blaise Bratter
Blaise Bratter is the Chief Contributor to CannabisIntel. Being involved in the Australian cannabis industry since legalisation in 2016, he is now Operations Manager for ASX listed company MGC Pharmaceuticals.

Get all the latest content delivered straight to your inbox.”